Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using 23Na-MRI at 3 T.

Accurate and non-invasive subtyping of localised renal tumours is an important unmet clinical challenge in uro-oncology and has significant implications for patient mortality and quality of life. Developing novel imaging methods to characterise and stratify indeterminate kidney tumours at an early stage has the potential to address this clinical challenge. Here we applied sodium MRI (23Na-MRI) to estimate kidney tumour sodium content in a prospectively recruited case series of 10 patients (mean age ± SD 64 ± 8 years; 7:3 male:female ratio). The patients had localised renal tumours which included six renal oncocytomas (ROs), two chromophobe renal cell carcinomas (chRCCs), three clear cell RCCs (ccRCC) and one papillary RCC (pRCC). The patients underwent 23Na-MRI at 3 T (3D sodium cones and double-angle B1 mapping) and 1H-MRI which included R2* mapping and intravoxel incoherent motion (IVIM) diffusion weighted imaging (DWI). The following imaging parameters were quantified within the renal tumours and in the normal-appearing kidney parenchyma: apparent total sodium concentration (TSC); apparent 23Na and 1H relaxation rates (R2*); perfusion fraction (fp); and diffusion coefficient (Dt). 23Na-MRI findings were correlated with conventional 1H-MRI measures of perfusion, hypoxia and cellularity. The mean apparent TSC in ccRCC and in pRCC were 135 ± 59 mM and 81 mM, respectively. The apparent TSC was significantly higher in ROs compared to chRCCs: 162 ± 58 mM vs. 71 ± 2 mM (p < 0.05). The apparent TSC inversely correlated with 1H-R2* (Spearman r = -0.39, p < 0.05). In conclusion, this study showed the feasibility and potential of using 23Na-MRI in renal tumours to probe sodium concentrations. These preliminary findings suggest a differential sodium content between benign ROs and malignant chRCCs. The inverse correlation between sodium concentration and 1H-R2* as a surrogate of hypoxia may indicate a biophysical relationship between the two which requires further validation in larger patient cohorts.

NMR in biomedicine. 2026 Aug [Epub]

Ines Horvat-Menih, Jonathan R Birchall, Maria J Zamora-Morales, Alice Bebb, Joshua D Kaggie, Frank Riemer, Andrew B Gill, Andrew N Priest, Marta Wylot, Iosif A Mendichovszky, Anne Y Warren, James Jones, James N Armitage, Thomas J Mitchell, Grant D Stewart, Mary A McLean, Ferdia A Gallagher

Department of Radiology, University of Cambridge, Cambridge, UK., Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital Helse Bergen, Bergen, Norway., Department of Pathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge., Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.